Why the study?
Do CRP gene polymorphisms (+942G>C, 1846C>T) increase cancer susceptibility in human populations?
Do CRP gene polymorphisms (+942G>C, 1846C>T) increase cancer susceptibility in human populations?
Genetic polymorphisms in the CRP gene (+942G>C and 1846C>T) are associated with an increased overall risk of cancer, particularly colorectal cancer.
Answers are grounded in this paper and cite their sources.
CRP polymorphisms may signal inherited cancer susceptibility; leaves open causal validation and screening utility in prospective studies.
Elevated levels of C-reactive protein (CRP) partially induced by polymorphisms in the CRP gene have been associated with human cancer. The purpose of this study was to test the hypothesis that CRP gene polymorphisms (+942G>C, 1846C>T) modify inherited susceptibility to cancer. We systematically identified the publications addressing the association of CRP gene polymorphisms with cancer susceptibility. Studies that fulfilled all inclusion criteria were considered eligible in this meta-analysis. We analyzed a total of 8 case-control studies. Individuals with the CC genotype were found to have an almost 4 fold higher risk of cancer than those with the GG or GC and GG genotypes. A significant association was also indicated in subgroup of colorectal cancer. Meta-analysis of 1846C>T polymorphism showed increased cancer risk in relation to the 1846 TT genotype (TT vs. CC: OR = 1.15, 95% CI = 1.01-1.31; TT vs. CT + CC; OR = 1.17, 95% CI = 1.03-1.32). Similar results were suggested in Caucasian populations and colorectal cancer. These data suggest that both +942G>C and 1846C>T polymorphisms in the CRP gene may influence cancer susceptibility.
No takes yet. Share an insight, caveat, or question.
Geng et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: